Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 14;81(6):620-622.
doi: 10.1016/j.jacc.2022.12.003.

Medication Use for Cardiovascular Disease Prevention in 40 Low- and Middle-Income Countries

JingJing Z Zhu, Jennifer Manne-Goehler, Anubha Agarwal, Silver K Bahendeka, Albertino Damasceno, Maja E Marcus, Sahar Saeedi Moghaddam, Sebastian Vollmer, Mark D Huffman, David Flood; Global Health & Population Project on Access to Care for Cardiometabolic Disease (HPACC)
Collaborators

Medication Use for Cardiovascular Disease Prevention in 40 Low- and Middle-Income Countries

JingJing Z Zhu et al. J Am Coll Cardiol. .

Abstract

Using nationally representative data from 40 low- and middle-income countries, the authors find very low use of important CVD preventive medications, including blood pressure lowering drugs, statins, and aspirin.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:. Treatment with statins, BP-lowering drugs, and aspirin among eligible individuals for the primary and secondary prevention of CVD in 40 low- and middle-income countries
*Primary prevention refers to individuals without CVD and predicted CVD risk >20%. Error bars represent 95% CIs.
See this image and copyright information in PMC

References

    1. Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: An Overview of Systematic Reviews. JAMA Cardiol. 2016. Jun 1;1(3):341–9. - PMC - PubMed
    1. Marcus ME, Manne-Goehler J, Theilmann M, et al. Use of statins for the prevention of cardiovascular disease in 41 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data. Lancet Glob Health. 2022; 10(3): e369–e79. - PMC - PubMed
    1. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011; 378(9798): 1231–43. - PubMed
    1. Shah NS, Huffman MD, Ning H, Lloyd-Jones DM. Trends in myocardial infarction secondary prevention: the National Health and Nutrition Examination Surveys (NHANES), 1999–2012. J Am Heart Assoc. 2015. Apr 22;4(4):e001709. - PMC - PubMed
    1. Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021. Sep 25;398(10306):1133–46. - PubMed

Publication types

MeSH terms